| 1. |
- Helczynski, L., et al.
(författare)
-
Cross Phase Modulation Induced Pulse Splitting - The Optical Axe
- 2000
-
Ingår i: Physica scripta. T. - 0281-1847. ; 84, s. 81-84
-
Tidskriftsartikel (refereegranskat)abstract
- An analytical as well as numerical analysis is made of the dynamics induced on a weak signal wave pulse by a co-propagating strong pump wave pulse in a nonlinear Kerr medium. Emphasis is given to the situation where the group velocity dispersion and the non-linearity of the signal pulse have opposite signs. In this defocusing situation, it is demonstrated that the pump splits the signal pulse into two frequency shifted pulse fragments which separate in time, asymptotically with constant separation velocity. Explicit analytical predictions for the velocity of separation are obtained and corroborated by numerical simulations.
|
|
| 2. |
- Anderson, Dan, 1943, et al.
(författare)
-
The optimal journey from A to B
- 2008
-
Ingår i: American Journal of Physics. ; 76:9, s. 863-866
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Desaix, Mats, et al.
(författare)
-
Nonlinear Schrödinger Solitons with non-zero velocities emerging from real symmetric initial conditions
- 2009
-
Konferensbidrag (refereegranskat)abstract
- Solutions of the nonlinear Schrodinger equation for initial conditions in the form of two separated sech-shaped in-phase pulsed,; are analyzed. It is found that; this initial condition, with appropriate amplitude, may give rise to, not; only stationary solitons, but also to symmetrically separating solitons, if the initial distance of separation is large enough. The condition for the generation of a separating soliton pair is derived from the Zakharov-Shabat eigenvalue problem using a variational approach.
|
|
| 4. |
- Desaix, M., et al.
(författare)
-
Nonlinear Schrödinger solitons with non-zero velocities emerging from real symmetric initial conditions
- 2008
-
Ingår i: in Proceedings of SIAM Conference on Nonlinear Waves and Coherent Structures, July 21-24, 2008, Rome, Italy, Society for Industrial and Applied Mathematics (SIAM), Philadelphia, PA, USA. ; , s. 51-
-
Konferensbidrag (refereegranskat)
|
|
| 5. |
- Desaix, M., et al.
(författare)
-
Nonlinear Schrödinger Solitons with non-zero velocities emerging from real symmetric initial conditions
- 2008
-
Ingår i: AIP Conference Proceedings. - : AIP. - 1551-7616 .- 0094-243X. ; , s. 299-303
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Solutions of the nonlinear Schrodinger equation for initial conditions in the form of two separated sech-shaped in-phase pulses are analyzed. It is found that this initial condition, with appropriate amplitude, may give rise to, not only stationary solitons, but also to symmetrically separating soli- tons, if the initial distance of separation is large enough. The condition for the generation of a separating soliton pair is derived from the Zakharov-Shabat eigenvalue problem using a variational approach.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Ludvigsson, Johnny, et al.
(författare)
-
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
- 2012
-
Ingår i: New England Journal of Medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 366:5, s. 433-442
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes.METHODS: We studied 334 patients, 10 to 20 years of age, with type 1 diabetes, fasting C-peptide levels of more than 0.3 ng per milliliter (0.1 nmol per liter), and detectable serum GAD65 autoantibodies. Within 3 months after diagnosis, patients were randomly assigned to receive one of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of placebo. The primary outcome was the change in the stimulated serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-month visit. Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate of hypoglycemia, and fasting and maximum stimulated C-peptide levels.RESULTS: The stimulated C-peptide level declined to a similar degree in all study groups, and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group (P=0.10). The use of GAD-alum as compared with placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate. Adverse events were infrequent and mild in the three groups, with no significant differences.CONCLUSIONS: Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period.
|
|
